Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 6/20 | 0.38 |
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30325739 | 0.93 | BTK (0.37) | FGFR1BTKEGFRCSNK2A2CSNK2A1 | |
| SCHEMBL30325774 | 0.92 | BTK (0.39) | FGFR1BTKEGFRCSNK2A2CSNK2A1 | |
| SCHEMBL30326048 | 0.92 | BTK (0.37) | FGFR1BTKEGFRCSNK2A2CSNK2A1 | |
| SCHEMBL30325665 | 0.91 | BTK (0.37) | BTKEGFRCSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL30325782 | 0.91 | CSNK2A2 (0.44) | BTKEGFRCSNK2A2CSNK2A1TNK2 | |
| SCHEMBL30325947 | 0.91 | BTK (0.38) | BTKEGFRCSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL30325990 | 0.90 | MAPT (0.41) | FGFR1BTKEGFRTNK2RIPK1 | |
| SCHEMBL30325873 | 0.90 | BTK (0.37) | BTKEGFRCSNK2A2CSNK2A1TNK2 | |
| SCHEMBL30326178 | 0.90 | CSNK2A2 (0.43) | FGFR1BTKEGFRCSNK2A2CSNK2A1 | |
| SCHEMBL30325768 | 0.89 | CSNK2A2 (0.36) | FGFR1BTKEGFRCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | claimed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | claimed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | FGFR1 1/4885BTK 168/4885EGFR 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.